{"disease":{"id":"lipid","name":"lipid"},"drugs":{"marketed":[{"drug_id":"evolocumab","indication_name":"Complex dyslipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Repatha","generic_name":"EVOLOCUMAB","company_name":"Repatha","drug_phase":"marketed","molecular_target":"PCSK9","drug_class":"PCSK9 Inhibitor [EPC]","quality_score":75,"revenue":"2100","mechanism":"Evolocumab, a human monoclonal IgG2, lowers LDL-C by inhibiting PCSK9 binding to LDLR, increasing LDLR availability to clear LDL."},{"drug_id":"atorvastatin","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"alirocumab","indication_name":"Complex dyslipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Praluent","generic_name":"ALIROCUMAB","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Proprotein convertase subtilisin/kexin type 9","drug_class":"PCSK9 Inhibitor [EPC]","quality_score":62,"revenue":"857","mechanism":"Praluent blocks the PCSK9 protein, which helps remove LDL cholesterol from the bloodstream, thereby reducing cholesterol levels."},{"drug_id":"laropiprant","indication_name":"Dyslipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LAROPIPRANT","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin D2 receptor","drug_class":"laropiprant","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"inositol","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inosital","generic_name":"INOSITOL","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"inositol","quality_score":null,"revenue":null,"mechanism":"Inosital works by influencing the metabolism of lipids in the body."},{"drug_id":"nicotinic-acid","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Niaspan","generic_name":"Nicotinic Acid","company_name":"Medpointe Pharm Hlc","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"Non-Standardized Food Allergenic Extract [EPC]","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"nicotinic-acid","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Niaspan","generic_name":"Nicotinic Acid","company_name":"Medpointe Pharm Hlc","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 2","drug_class":"Non-Standardized Food Allergenic Extract [EPC]","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"ciprofibrate","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipanor","generic_name":"CIPROFIBRATE","company_name":"Winthrop Pharmaceuticals UK Limited","drug_phase":"marketed","molecular_target":"Peroxisome proliferator-activated receptor alpha","drug_class":"ciprofibrate","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"ezetrol","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ezetrol","company_name":"NVP Healthcare","drug_phase":"phase_1","molecular_target":"Sodium/bile acid cotransporter, Niemann-Pick C1-like protein 1, Niemann-Pick C1-like protein 1","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"ezetrol","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ezetrol","company_name":"NVP Healthcare","drug_phase":"phase_1","molecular_target":"Sodium/bile acid cotransporter, Niemann-Pick C1-like protein 1, Niemann-Pick C1-like protein 1","drug_class":"","quality_score":12,"revenue":null,"mechanism":null},{"drug_id":"niaspan","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Niaspan","company_name":"Cedars-Sinai Medical Center","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 3, Nicotinate-nucleotide pyrophosphorylase [carboxylating], Nicotinamide N-methyltransferase","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"niaspan","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Niaspan","company_name":"Cedars-Sinai Medical Center","drug_phase":"marketed","molecular_target":"Hydroxycarboxylic acid receptor 3, Nicotinate-nucleotide pyrophosphorylase [carboxylating], Nicotinamide N-methyltransferase","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"saroglitazar","indication_name":"Diabetic dyslipidemia associated with type 2 diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipaglyn","generic_name":"SAROGLITAZAR","company_name":"Cadila Healthcare","drug_phase":"marketed","molecular_target":"Peroxisome proliferator-activated receptor alpha","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"levothyroxine-sodium","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unithroid","generic_name":"LEVOTHYROXINE SODIUM","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Thyroid hormone receptor beta","drug_class":"l-Thyroxine","quality_score":70,"revenue":null,"mechanism":"Unithroid works by replacing or supplementing the thyroid hormone thyroxine, which is produced by the thyroid gland."},{"drug_id":"fluvastatin","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lescol","generic_name":"FLUVASTATIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":65,"revenue":null,"mechanism":"Fluvastatin sodium inhibits HMG-CoA reductase, reducing cholesterol biosynthesis and increasing LDL receptor activity, lowering plasma cholesterol."},{"drug_id":"colestilan","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Colestimide","generic_name":"colestilan","company_name":"Tanabe Pharma Corporation","drug_phase":"discontinued","molecular_target":"","drug_class":"colestilan","quality_score":0,"revenue":null,"mechanism":"Colestimide works by inhibiting the absorption of cholesterol and/or phosphorus in the intestines."},{"drug_id":"dextrothyroxine","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Choloxin","generic_name":"DEXTROTHYROXINE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Thyroid hormone receptor","drug_class":"dextrothyroxine","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"nicomol","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cholexamin","generic_name":"NICOMOL","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"nicomol","quality_score":null,"revenue":null,"mechanism":"Cholexamin works by inhibiting the enzyme responsible for cholesterol synthesis."},{"drug_id":"colestipol","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Colestid","generic_name":"Colestipol","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Bile Acid Sequestrant","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"lopid","indication_name":"Treatment of adult patients with Type IV hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopid","generic_name":"Gemfibrozil","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PPAR-alpha (Peroxisome Proliferator-Activated Receptor Alpha)","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"lopid","indication_name":"Treatment of adult patients with Type V hyperlipidemia with very high serum triglyceride elevations (>2,000 mg/dL) presenting risk of pancreatitis unresponsive to diet","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopid","generic_name":"Gemfibrozil","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"PPAR-alpha (Peroxisome Proliferator-Activated Receptor Alpha)","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"ezetimibe","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zetia","generic_name":"EZETIMIBE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Niemann-Pick C1-like protein 1","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":"Zetia works by blocking the absorption of cholesterol in the small intestine."},{"drug_id":"ezetimibe","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zetia","generic_name":"EZETIMIBE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Niemann-Pick C1-like protein 1","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":65,"revenue":null,"mechanism":"Zetia works by blocking the absorption of cholesterol in the small intestine."},{"drug_id":"probucol","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorelco","generic_name":"PROBUCOL","company_name":"","drug_phase":"marketed","molecular_target":"Serine protease hepsin","drug_class":"probucol","quality_score":28,"revenue":null,"mechanism":""},{"drug_id":"livalo","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Livalo","company_name":"Kowa Research Institute, Inc.","drug_phase":"discontinued","molecular_target":"Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, Retinoic acid receptor RXR-alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"simvastatin","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"levothyroxin","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"levothyroxin","company_name":"Ain Shams University","drug_phase":"marketed","molecular_target":"THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"thyroxine","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Thyroxine","company_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","drug_phase":"marketed","molecular_target":"THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"vascepa","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vascepa","company_name":"University of Louisville","drug_phase":"marketed","molecular_target":"Diacylglycerol O-acyltransferase 1","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"praluent","indication_name":"Complex dyslipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Praluent","company_name":"Regeneron Pharmaceuticals","drug_phase":"marketed","molecular_target":"Proprotein convertase subtilisin/kexin type 9","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"colextran","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dextran 2-(Diethylamino)Ethyl Ether","generic_name":"COLEXTRAN","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"colextran","quality_score":null,"revenue":null,"mechanism":"Colextran works by binding to and removing excess cholesterol from the bloodstream."},{"drug_id":"cholestyramine","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Questran Light","generic_name":"CHOLESTYRAMINE","company_name":"Bristol Myers","drug_phase":"marketed","molecular_target":"","drug_class":"Bile Acid Sequestrant [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"myoinositol","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Myoinositol","company_name":"University of Colorado, Denver","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"levothyroxine","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Synthroid","generic_name":"levothyroxine","company_name":"Generic (originally multiple — AbbVie/Synthroid)","drug_phase":"marketed","molecular_target":"THAP domain-containing protein 1, Macrophage migration inhibitory factor, Malate dehydrogenase, mitochondrial","drug_class":"Thyroid hormone","quality_score":10,"revenue":null,"mechanism":"Synthetic thyroxine (T4) that replaces deficient thyroid hormone, restoring normal metabolism, growth, and development."},{"drug_id":"niacin","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nicotinic Acid","generic_name":"NIACIN","company_name":"MEDPOINTE PHARM HLC","drug_phase":"marketed","molecular_target":"NAD synthase","drug_class":"Vitamin C [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"niacin","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nicotinic Acid","generic_name":"NIACIN","company_name":"MEDPOINTE PHARM HLC","drug_phase":"marketed","molecular_target":"NAD synthase","drug_class":"Vitamin C [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"nicotinyl-alcohol","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pyridylcarbinol","generic_name":"nicotinyl alcohol","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"nicotinyl alcohol","quality_score":null,"revenue":null,"mechanism":"Pyridylcarbinol works by providing the body with a precursor to NAD+, a crucial coenzyme involved in energy metabolism."},{"drug_id":"fenofibrate","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tricor (Micronized)","generic_name":"FENOFIBRATE","company_name":"Salix","drug_phase":"marketed","molecular_target":"PPARα","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Fenofibrate activates PPARα, enhancing lipolysis and reducing triglycerides, while increasing HDL-cholesterol and uric acid excretion."},{"drug_id":"fenofibrate","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tricor (Micronized)","generic_name":"FENOFIBRATE","company_name":"Salix","drug_phase":"marketed","molecular_target":"PPARα","drug_class":"Peroxisome Proliferator Receptor alpha Agonist [EPC]","quality_score":80,"revenue":null,"mechanism":"Fenofibrate activates PPARα, enhancing lipolysis and reducing triglycerides, while increasing HDL-cholesterol and uric acid excretion."},{"drug_id":"rosuvastatin","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crestor","generic_name":"rosuvastatin","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":74,"revenue":null,"mechanism":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor."},{"drug_id":"lipitor","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"clofibrate","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipavil","generic_name":"CLOFIBRATE","company_name":"","drug_phase":"marketed","molecular_target":"Peroxisome proliferator-activated receptor alpha","drug_class":"clofibrate","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"olmesartan","indication_name":"hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"olmesartan medoxomil-hydrochlorothiazide","generic_name":"OLMESARTAN","company_name":"Cosette","drug_phase":"marketed","molecular_target":"","drug_class":"Thiazide Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":"Olmesartan works by blocking the action of a hormone that causes blood vessels to constrict, allowing blood vessels to relax and blood pressure to decrease."},{"drug_id":"bezafibrate","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Befizal","generic_name":"BEZAFIBRATE","company_name":"","drug_phase":"marketed","molecular_target":"Fatty acid-binding protein, intestinal","drug_class":"bezafibrate","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hctz","indication_name":"hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lisinopril/HCTZ","generic_name":"HCTZ","company_name":"Direct_Rx","drug_phase":"marketed","molecular_target":"","drug_class":"Thiazide Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"icosapent-ethyl","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vascepa","generic_name":"ICOSAPENT ETHYL","company_name":"Amarin Pharms","drug_phase":"marketed","molecular_target":"Diacylglycerol O-acyltransferase 1","drug_class":"icosapent ethyl","quality_score":43,"revenue":null,"mechanism":""},{"drug_id":"choline-fenofibrate","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trilipix","generic_name":"CHOLINE FENOFIBRATE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Fatty acid-binding protein, intestinal","drug_class":"Peroxisome Proliferator Receptor alpha Agonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"choline-fenofibrate","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trilipix","generic_name":"CHOLINE FENOFIBRATE","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Fatty acid-binding protein, intestinal","drug_class":"Peroxisome Proliferator Receptor alpha Agonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"pitavastatin","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Livalo","generic_name":"PITAVASTATIN","company_name":"Kowa Co","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"cerivastatin","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Baycol","generic_name":"CERIVASTATIN","company_name":"Bayer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"cerivastatin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"aprocitentan","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tryvio","generic_name":"APROCITENTAN","company_name":"Idorsia","drug_phase":"marketed","molecular_target":"","drug_class":"Endothelin Receptor Antagonist [EPC]","quality_score":60,"revenue":null,"mechanism":"Tryvio works by blocking the action of endothelin, a protein that constricts blood vessels and increases blood pressure."},{"drug_id":"lovastatin","indication_name":"Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mevacor","generic_name":"LOVASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver."},{"drug_id":"chembl-chembl1496","indication_name":"Reduce LDL-C in primary hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ROSUVASTATIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"lovastatin","indication_name":"Mixed hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mevacor","generic_name":"LOVASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver."},{"drug_id":"fluvastatin-sodium","indication_name":"Reduce LDL-C in Primary Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLUVASTATIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Fluvastatin inhibits HMG-CoA reductase, reducing cholesterol synthesis."},{"drug_id":"caduet","indication_name":"Primary Hyperlipidemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."}],"pipeline":[],"offLabel":[],"totalMarketed":56,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT05221528","title":"Association Between Lipid Profiles and Cardiovascular Events","phase":"","overall_status":"UNKNOWN","enrollment_count":4234339,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT05285085","title":"Real World Evidence Study of Statin Use in Brazil","phase":"","overall_status":"COMPLETED","enrollment_count":2133900,"lead_sponsor_name":"Hospital Israelita Albert Einstein","has_results":false},{"nct_id":"NCT04067297","title":"Using Big Data to Conduct Innovative Cardiovascular Clinical Trials","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500000,"lead_sponsor_name":"Institute for Clinical Evaluative Sciences","has_results":false},{"nct_id":"NCT06622304","title":"Exploring the Effects of Antihypertensive and Lipid-Lowering Drugs on Inflammatory Cytokine Levels","phase":"","overall_status":"COMPLETED","enrollment_count":250736,"lead_sponsor_name":"Guangzhou Institute of Respiratory Disease","has_results":false},{"nct_id":"NCT06338956","title":"Optimal Attained LDL-Cholesterol Levels in Patients Who Achieved ≥50% LDL Reduction After PCI","phase":"","overall_status":"COMPLETED","enrollment_count":135877,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT06903897","title":"Social Needs Screening and Chronic Diseases Study (WE CARE)","phase":"NA","overall_status":"RECRUITING","enrollment_count":68000,"lead_sponsor_name":"University of Massachusetts, Worcester","has_results":false},{"nct_id":"NCT03344224","title":"Pre-operative Blood Lipid Level and Post-operative Major Adverse Cardiac Event","phase":"","overall_status":"COMPLETED","enrollment_count":50000,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT01764633","title":"Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":27564,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03065543","title":"Hyperlipidemia Therapy TERCET Zabrze Registry","phase":"","overall_status":"UNKNOWN","enrollment_count":25000,"lead_sponsor_name":"Silesian Centre for Heart Diseases","has_results":false},{"nct_id":"NCT03862183","title":"Hospital-level Variation in the Management of Blood Pressure and Low-density Lipoprotein in the Outpatient Hypertensives in China-a Cross Sectional Study","phase":"","overall_status":"UNKNOWN","enrollment_count":21000,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT07308314","title":"Taining Golden Lake Comprehensive Chronic Disease Management Initiative","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"First Affiliated Hospital of Fujian Medical University","has_results":false},{"nct_id":"NCT05614765","title":"Evaluation of Dyslipidemia Management After Statin and Ezetimibe Complex Treatment","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18000,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT02285166","title":"Specified Drug-use Survey of the Granular Capsule Formulation of Omega-3 Fatty Acid Ethyl Esters: OCEAN3","phase":"","overall_status":"COMPLETED","enrollment_count":15330,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT05889143","title":"A Study to Evaluate the Efficacy and Safety of CREZET Tablet","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT03799185","title":"Dyslipidemia Prevalence, Perception, Treatment, and Awareness in the Tunisian Population","phase":"","overall_status":"COMPLETED","enrollment_count":13610,"lead_sponsor_name":"Association Tunisienne d'Etude & de Recherche sur l'Athérosclérose","has_results":false},{"nct_id":"NCT04118348","title":"Evaluating the Efficacy of Pediatric Lipid Screening Alerts","phase":"NA","overall_status":"COMPLETED","enrollment_count":13340,"lead_sponsor_name":"Geisinger Clinic","has_results":true},{"nct_id":"NCT05542719","title":"Mexican Registry of Dyslipidemia in Patients at High Risk and Very High Risk of Atherosclerotic Cardiovascular","phase":"","overall_status":"UNKNOWN","enrollment_count":13166,"lead_sponsor_name":"Coordinación de Investigación en Salud, Mexico","has_results":false},{"nct_id":"NCT00358943","title":"International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT07515560","title":"Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT07409636","title":"A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Adult Patients","phase":"","overall_status":"COMPLETED","enrollment_count":11991,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02835287","title":"Diabetes Complication Control in Community Clinics (D4C) Trial","phase":"NA","overall_status":"UNKNOWN","enrollment_count":11132,"lead_sponsor_name":"Tulane University","has_results":false},{"nct_id":"NCT04554953","title":"A Combination Drug Including Fimasartan and Statins in Patients With Hypertension and Dyslipidemia","phase":"","overall_status":"COMPLETED","enrollment_count":10877,"lead_sponsor_name":"Boryung Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT03071692","title":"Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":10544,"lead_sponsor_name":"Kowa Research Institute, Inc.","has_results":true},{"nct_id":"NCT04442334","title":"The European NAFLD Registry","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Newcastle University","has_results":false},{"nct_id":"NCT03418974","title":"Safety and Efficacy of Statins for Chinese Patients With Dyslipidemia","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04271280","title":"Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events","phase":"","overall_status":"COMPLETED","enrollment_count":9559,"lead_sponsor_name":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","has_results":true},{"nct_id":"NCT03973931","title":"Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications","phase":"NA","overall_status":"COMPLETED","enrollment_count":9501,"lead_sponsor_name":"University of Colorado, Denver","has_results":true},{"nct_id":"NCT01420016","title":"Prioritized Clinical Decision Support (CDS) to Reduce Cardiovascular Risk","phase":"NA","overall_status":"COMPLETED","enrollment_count":7914,"lead_sponsor_name":"HealthPartners Institute","has_results":true},{"nct_id":"NCT06543706","title":"Metabolic Syndrome and Related Diseases in Healthcare Workers","phase":"","overall_status":"COMPLETED","enrollment_count":7432,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06115213","title":"The North Kynouria Project","phase":"NA","overall_status":"UNKNOWN","enrollment_count":7000,"lead_sponsor_name":"University Hospital, Ioannina","has_results":false},{"nct_id":"NCT04212520","title":"Predictive Value of Non-fasting Blood Lipid Levels for Cardiovascular Events in Community Population(PICC Study)","phase":"","overall_status":"RECRUITING","enrollment_count":6500,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT06186037","title":"Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":6356,"lead_sponsor_name":"Saint Vincent's Hospital, Korea","has_results":false},{"nct_id":"NCT02991534","title":"Cardiovascular Risk Screening and Risk Reduction in Women Vets","phase":"NA","overall_status":"COMPLETED","enrollment_count":6009,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT05845424","title":"High-intensity Statin and Ezetimibe Therapy for Asymptomatic Patients With Positive Coronary Calcium","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT07350486","title":"LLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"First Hospital of China Medical University","has_results":false},{"nct_id":"NCT04829149","title":"Statin Monotherapy and Rosuzet Tab.(Rosuvastatin/Ezetimibe) Administration in Patients With Dyslipidemia in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":5717,"lead_sponsor_name":"Hanmi Pharmaceutical Company Limited","has_results":false},{"nct_id":"NCT05184179","title":"Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab","phase":"","overall_status":"COMPLETED","enrollment_count":5450,"lead_sponsor_name":"Daewoong Pharmaceutical Co. LTD.","has_results":false},{"nct_id":"NCT03748420","title":"Medication Adherence Clinical Decision Support","phase":"NA","overall_status":"COMPLETED","enrollment_count":5421,"lead_sponsor_name":"HealthPartners Institute","has_results":true},{"nct_id":"NCT05450575","title":"An Observational Study to Evaluate Effectiveness and Safety of Amosartan Q Tablet","phase":"","overall_status":"COMPLETED","enrollment_count":5400,"lead_sponsor_name":"Hanmi Pharmaceutical Company Limited","has_results":false},{"nct_id":"NCT02867813","title":"Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":5035,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT02993120","title":"Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":5006,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04579367","title":"Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","has_results":false},{"nct_id":"NCT04402086","title":"Rheumatology Patient Registry and Biorepository","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Yale University","has_results":false},{"nct_id":"NCT05645367","title":"Associations of Lipid Measures With Premature Myocardial Infarction: a Cross-sectional Study","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Yue LI","has_results":false},{"nct_id":"NCT03939039","title":"From Known to New Genes in Dyslipidemia","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06831162","title":"Evaluating the Effectiveness of a Multi-level Health-Related Social Needs Initiative","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":4809,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":false},{"nct_id":"NCT03329729","title":"PLATOREL® STUDY IN CARDIOVASCULAR RISΚ ASSESMENT","phase":"","overall_status":"COMPLETED","enrollment_count":4700,"lead_sponsor_name":"Elpen Pharmaceutical Co. Inc.","has_results":false},{"nct_id":"NCT06258005","title":"PocDoc Lipids Out-of-Surgery Study","phase":"","overall_status":"COMPLETED","enrollment_count":4256,"lead_sponsor_name":"Vital Signs Solutions Ltd","has_results":false},{"nct_id":"NCT05039034","title":"Screening and Management of High-risk Populations of Stroke in Dehui City","phase":"","overall_status":"COMPLETED","enrollment_count":4100,"lead_sponsor_name":"Yi Yang","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}